Novel curcumin analog (cis-trans curcumin) as ligand to adenosine receptors A2A and A2B: potential for therapeutics
- 1 January 2021
- journal article
- research article
- Published by Elsevier BV in Pharmacological Research
- Vol. 165, 105410
- https://doi.org/10.1016/j.phrs.2020.105410
Abstract
No abstract availableKeywords
Funding Information
- American Chemical Society Petroleum Research Fund
- National Institute of General Medical Sciences
This publication has 58 references indexed in Scilit:
- Adenosine receptors as drug targets — what are the challenges?Nature Reviews Drug Discovery, 2013
- The A2b Adenosine Receptor Modulates Glucose Homeostasis and ObesityPLOS ONE, 2012
- Controlling murine and rat chronic pain through A 3 adenosine receptor activationThe FASEB Journal, 2012
- A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activationLaboratory Investigation, 2011
- Efficacy of turmeric (curcumin) in pain and postoperative fatigue after laparoscopic cholecystectomy: a double-blind, randomized placebo-controlled studySurgical Endoscopy, 2011
- Recent developments in adenosine receptor ligands and their potential as novel drugsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Pain-relieving prospects for adenosine receptors and ectonucleotidasesTrends in Molecular Medicine, 2011
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An UpdatePharmacological Reviews, 2011
- Adenosine A1 receptors mediate local anti-nociceptive effects of acupunctureNature Neuroscience, 2010
- Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studiesPurinergic Signalling, 2006